WEBULL
WebtradeDownload

STAAR Surgical (STAA) Unveils Buyback, Is It Still Below Fair Value?

Simply Wall St · 2d ago

STAAR Surgical buyback draws investor focus

STAAR Surgical (STAA) has put a fresh spotlight on its stock with a newly approved US$50 million share repurchase program, funded from free cash flow and cash on hand.

For context, STAAR Surgical’s 1-day share price return declined 3.64% to US$19.08, extending a 7-day drop of 10.17% and a 90-day slide of 34.86%. The 1-year total shareholder return is down 28.67% as investors weigh the new buyback against an ongoing fiduciary investigation and a much deeper 5-year total shareholder return decline of 85.16%.

Benchmark your view on STAAR Surgical against a curated field of others in similar territory by scanning the 16 high quality undiscovered gems, which combine beaten-down share prices with solid fundamentals.

Bulls see STAAR Surgical using buybacks and recent profit growth to reset the story. Bears point to years of share price damage and an active investigation. Which side does the valuation actually support next?

Most Popular Narrative: 36% Undervalued

On Simply Wall St’s most followed narrative, STAAR Surgical screens as materially cheaper than its modeled fair value of $29.67 compared to the last close at $19.08. This puts the new buyback into a very different light for anyone thinking about capital allocation.

STAAR Surgical has significant cash reserves and no debt, providing a strong financial base to navigate the current challenges, reduce production outputs temporarily, and invest selectively in growth initiatives, potentially stabilizing earnings and providing upside if conditions improve.

See why 7 investors see STAAR Surgical as 36% undervalued.

Result: Fair Value of $29.67 (UNDERVALUED)

Still, STAAR Surgical relies heavily on a single distributor in China and faces competitive pressure that could unsettle revenue expectations if conditions soften again.

Find out about the key risks to this STAAR Surgical narrative.

Next Steps

Mixed on STAAR Surgical after all of that? Move quickly, review both sides of the story, and weigh the 3 key rewards and 1 important warning sign against your own read of the numbers.

Looking for more STAAR Surgical sized opportunities?

If STAAR Surgical has sharpened your focus on valuation and risk, do not stop here. Broaden your watchlist now or you could miss stronger setups elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.